# COA Integration Private-Preview Validation

## Verified Representative — Retatrutide 30 mg

The private route `/coa/retatrutide-30mg` rendered a batch-matched report for lot `A100001` and Ethos report `26EA0701-027`. The page displayed the sample name `RETA 30 MG`, labeled strength `30 mg/vial`, HPLC method, test date `2026-07-10`, identity confirmation under USP `<621>`, measured content `30.64 mg/vial`, label specification `30 mg/vial`, and reported `>99% chromatographic purity`.

The laboratory panel identified Ethos Analytics Laboratory, the Phoenix address, ISO/IEC 17025:2017 accreditation reference `117798`, receipt and completion dates, Laboratory Director signature attribution, and the explicit limitation that the result applies only to lot `A100001` in the identified report. The `View signed COA PDF` action points to `/manus-storage/coa-retatrutide-30mg-lot-a100001_6e590ff9.pdf`.

The rendered page retained the product image, shared logo, product-return link, navy/silver visual system, and research-only limitation. No analytical value was generalized beyond the matched lot.

## Verified GLOW 70 mg

After the owner supplied the matching report, the private route `/coa/ghk-cu-bpc157-tb500-glow` changed from pending to **Batch-matched report available**. It displays lot `F100001`, Ethos report `26EA0701-035`, sample name `GLOW 70 MG`, labeled component strength `50/10/10 mg/vial`, HPLC test date `2026-07-10`, identity confirmation under USP `<621>`, measured GHK-Cu / BPC-157 / TB-500 contents of `51.16 / 10.14 / 10.26 mg/vial`, and reported `>99% chromatographic purity`.

The page identifies Ethos Analytics Laboratory, its Phoenix address and accreditation reference, the exact lot-and-report scope limitation, receipt and completion dates, Laboratory Director attribution, and the durable signed PDF path `/manus-storage/coa-glow-70mg-lot-f100001_016de57d.pdf`. No value is generalized beyond lot `F100001`.

## Product-Detail Status Card

The private route `/product/retatrutide-30mg` now displays `Batch-matched Ethos report 26EA0701-027 is available for lot A100001` and links to the verified COA page. The link label includes the exact report-supported `>99% chromatographic purity` result and the matched lot rather than a catalog-wide claim. The product price remains account-gated on this detail route, and no cart or checkout action was performed during review.

## Desktop Route and Compatibility Review

Full-page desktop captures confirmed that the verified Retatrutide and GLOW COA states remain visually distinct and readable. Both pages include the complete metadata grid, analytical-result panel, laboratory-and-scope panel, PDF action, and research-only footer. GLOW now displays only report-supported values from lot `F100001` rather than its former pending interface.

The corrected canonical route `/product/ghk-cu-100mg` displays the 100 mg vial, `$80` account-gated product record, Ethos report `26EA0701-033`, lot `D100001`, and `>99% chromatographic purity` status. The former `/product/ghk-cu-50mg` URL resolves through the compatibility lookup to the same 100 mg product and report, preventing legacy links from breaking while new catalog links use the accurate identifier.

## Mobile and Document-Link Validation

Full-page 375 px captures confirmed that the Retatrutide and GLOW verified COA metadata, analytical results, laboratory scope, and download actions remain readable and contained. The GLOW product-detail page now displays the matched report ID, lot, purity result, and COA link while retaining its five discoverable Full Details tabs, research-only notice, and related-product grid without horizontal overflow.

All 16 durable COA paths followed storage redirects to **HTTP 200** responses with `application/pdf` content types. No PDF content was modified during staging or upload.

## Final Private Validation

TypeScript completed without errors. All **81 active tests** passed, including all 16 exact report mappings, durable document URL patterns, GHK-Cu compatibility alias, batch-scope language, and boutique hero-copy assertions. Four credential-dependent workflow tests remained intentionally skipped. The production build succeeded with only the existing bundle-size advisory.

Retatrutide 30 mg remains `$200`, the finalized catalog remains 16 products with four signature blends, and the read-only integration-status procedure reports both configured and approved flags as `true`. No email, cart mutation, order, payment, rate, label, postage, pickup, fulfillment, database, secret, DNS, domain, checkpoint, or production deployment action occurred during COA integration and validation.
